CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.
In a major setback in the development of HIV fusion inhibitors, Roche and Trimeris announced Monday that they have halted development of their experimental drug T-1249, a highly touted second-generation version of their already approved medication Fuzeon. Clinical development of the compound was put on indefinite hold due to challenges in manufacturing the complex medication, according to company officials. The current batch of T-1249 available is not suitable for use in advanced clinical trials, they added. However, basic research into a formulation of T-1249 that is easier to mass produce will continue at the pharmaceutical companies. AIDS experts had viewed T-1249 as the leading fusion inhibitor candidate in development based on previous reports that the compound was more effective than Fuzeon, the only approved fusion inhibitor, in preventing HIV from attaching to and infecting immune system cells. Company officials say the compound is effective but just too difficult to manufacture. "T-1249's safety, efficacy, and tolerability profile as determined to date in Phase I trials were not the reasons for this decision," Miklos Salgo, director of Roche Virology, Clinical Science, wrote to T-1249 and Fuzeon investigators. "The challenges we have encountered with T-1249 are not shared by Fuzeon. Thus, this action has no impact whatsoever on Fuzeon or on the continued use of Fuzeon by patients." Company officials say that despite halting development of the drug, Roche and Trimeris will manufacture enough of the medication to provide it free to all patients currently enrolled in a human trial of the medication through the study's 96-week endpoint. The companies also plan to continue to develop other fusion inhibitor candidates and announced the signing of a three-year extension of a research agreement to "work together to discover new HIV fusion inhibitors and to pursue improved formulations and delivery technologies which may be applicable to Fuzeon, T-1249, and future peptide fusion inhibitors."
From our Sponsors
Most Popular
Watch Now: Pride Today
Latest Stories
BREAKING: Supreme Court to decide whether states can ban transgender women & girls from sports
July 03 2025 10:02 AM
True
Who was Jimmy Swaggart, the late, anti-LGBTQ+, disgraced televangelist?
July 02 2025 5:40 PM
Wisconsin Supreme Court strikes down abortion ban from 1849
July 02 2025 11:55 AM
The deadly 'big beautiful' budget bill will turn America into a morgue
July 02 2025 11:28 AM